47 results about "Occludin" patented technology

The invention belongs to the technical field of biological medicine, and particularly relates to application of garlic polysaccharide in preparation of a product for repairing intestinal injury caused by constipation. An embodiment verifies that the garlic polysaccharide can effectively repair intestinal physical, chemical and immune barrier injuries caused by constipation, and by up-regulating expression of tight junction proteins (such as ZO-1 and Occludin) and reducing expression of Claudin-1, the garlic polysaccharide can enhance tight junction between intestinal epithelial cells and reduce intestinal permeability; besides, the garlic polysaccharide can promote secretion of intestinal mucoprotein and enhance the protection function of the intestinal mucous layer by up-regulating expression of MUC2 and MUC4 genes. The invention discloses a multi-aspect action mechanism of the garlic polysaccharide in repairing intestinal injury caused by constipation, and the garlic polysaccharide is expected to become a novel intestinal repairing agent for treating constipation and related complications thereof.

The invention provides thesium chinense polysaccharide as well as a preparation method and application thereof, compared with the prior art, neutral polysaccharide TP1 is efficiently extracted from thesium chinense by adopting a hot water extraction method, the neutral polysaccharide TP1 mainly comprises fructose, glucose and galactose according to a molar ratio of 44.7: 33.8: 17.9, and the molecular weight Mw of the TP1 measured by adopting a GPC-RI-MALS chromatographic method is 5377Da. The invention also researches the protective effect of thesium chinense polysaccharide on DSS-induced colitis. The TP1 reduces the loss of intestinal tight junction proteins (Claudin-1, Occludin and ZO-1), regulates the abundance of bacteria in the intestinal tract and enriches bacteria (ruminococcus, lactobacillus and bifidobacterium) capable of generating SCFAs, in addition, the TP1 increases the expression of GPR41 and GPR43 receptors in colon tissues, and the symptoms of colitis are relieved by reducing oxidative stress and inflammatory cytokine levels through the GPR41 and GPR43 receptors mediated by the SCFAs. The thesium chinense polysaccharide TP1 prepared by the invention can be used for preparing medicines for preventing and treating colitis and also can be used for preparing food.

The invention discloses a marker for diagnosing intestinal epithelial barrier injury induced by uremic toxin and application of the marker, and belongs to the technical field of biomedicine. Human colon cancer cells (Caco-2) are adopted to establish intestinal epithelial injury models under different urea treatment conditions, and the optimal concentration and time are screened through CCK-8 and immune blot. According to the present invention, RT-qPCR is adopted to detect the expression of lncRNANEAT1 and miR-122-5p, Westernblot and an immunofluorescence method are adopted to detect the expression of tight junction proteins Occludin, ZO-1 and Claudin-1, fluorescein sodium is adopted to detect the cell para-permeability of an intestinal epithelial injury model, and the combination of miR-122-5p with lncRNANEAT1 and Occludin is detected through bioinformatics analysis and dual-luciferase reporter gene analysis; the result shows that the lncRNANEAT1 can be used for protecting intestinal epithelial barrier injury induced by uremia toxin by regulating the miR-122-5p / Occludin axis. The discovery reveals an action mechanism of the lncRNANEAT1 in uremia toxin induced intestinal epithelial barrier injury, and provides a new thought and method for reducing complications of uremia patients and improving life quality.

This barrier function enhancer, this occludin mRNA expression promoter, this claudin-1 mRNA expression promoter, this claudin-4 mRNA expression promoter, this tight junction protein-1 mRNA expression promoter, and this tight junction protein-2 mRNA expression promoter contain ganoderic acid as an active ingredient.

The invention discloses a probiotic which is derived from human milk and has the effects of resisting oxidation, resisting inflammation, protecting tissues and protecting intestinal barriers and application of the probiotic. Lactobacillus paracasei DPUMW-M14-9 is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms, and the preservation number is CCTCC M 20252990. The strain has the characteristics of acid resistance, bile resistance, strong oxidation resistance, high surface hydrophobicity, self-aggregation capability and the like. The lactobacillus paracasei DPUMW-M14-9 can effectively adhere to epithelial cells, promote cell proliferation and regulate and control the process of a cell cycle. The bacterial strain can be used for inhibiting proinflammatory cytokines (TNF-alpha, IL-6 and IL-1beta) induced by lipopolysaccharide (LPS) and repairing tight junction proteins (ZO-1, Occludin and Claudin-1) at the same time, so that the integrity of epithelial cells is enhanced.

The invention discloses recombinant lactobacillus casei for expressing sialyltransferase ST6GALNAC1, and belongs to the technical field of genetic engineering and microorganisms. The recombinant bacterium is obtained by cloning an ST6GALNAC1 gene to a pPG612 vector and electrically transforming the ST6GALNAC1 gene into lactobacillus casei ATCC393. Experiments show that the engineering bacterium can significantly enhance glycosylation modification of intestinal mucoprotein MUC2, improve expression of tight junction proteins (ZO-1, Occludin and Claudin-1), inhibit activation of a p38 / MAPK inflammation pathway and regulate an intestinal flora structure, so that intestinal injury and systemic inflammatory response caused by salmonella are effectively relieved. The invention provides a strain basis and technical support for developing a novel oral microecological preparation.

The present application relates to the use of vascular BACE1 as a therapeutic target for diseases related to cerebral small vessel injury. Specifically, it relates to the use of a substance that reduces the expression level of the beta-secretase (BACE1) gene and / or an inhibitor of the enzymatic activity of BACE1 protein in the preparation of a drug for treating or alleviating cerebrovascular disease, wherein the disease related to cerebral small vessel injury is preferably Alzheimer's disease, amyloid cerebral small vessel disease, and vascular dementia. The inventors have found that an increase in the content of BACE1 can cleave the tight junction protein Occludin, resulting in the degradation and loss of tight junction proteins between vascular endothelial cells, causing the structure and function of the blood-brain barrier to be damaged, ultimately leading to cerebral microbleeds and cognitive dysfunction and other pathological phenotypes of diseases related to cerebral small vessel injury; inhibition of the enzymatic activity of BACE1 can improve these pathological phenotypes of diseases related to cerebral small vessel injury.

The invention discloses lactobacillus helveticus capable of relieving rheumatoid arthritis and application of the lactobacillus helveticus, and belongs to the technical field of microorganisms. A strain of lactobacillus helveticus CCFM1501 is screened out, the lactobacillus helveticus CCFM1501 can produce cell wall protease, amino-peptidase and aromatic transaminase at high yield, and has the effect of relieving rheumatoid arthritis, and the specific effects are that the thickness of a posterior claw of a rat with rheumatoid arthritis is reduced, and knee joint injury is improved; the content of proinflammatory cytokines in the serum of rheumatoid arthritis rats is reduced, the content of anti-inflammatory cytokines IL-10 in the serum of the rheumatoid arthritis rats is increased, the content of arthritis specific antibodies in the serum of the rheumatoid arthritis rats is reduced, the mRNA relative expression quantity of colonic tight junction proteins ZO-1 and Occludin in the rheumatoid arthritis rats is increased, and the anti-inflammatory activity of the rheumatoid arthritis rats is improved. The content of acetic acid and butyric acid in excrement of rats with rheumatoid arthritis is increased.

The invention belongs to the technical field of cosmetics or skin injury repair preparations, and discloses application of cistanche deserticola polysaccharide in preparation of products for protecting skin barriers. The invention discloses a mechanism of the cistanche deserticola polysaccharide for protecting a skin barrier. The cistanche deserticola polysaccharide can promote proliferation of HaCaT cells and can also promote expression of tight junction proteins Claudin-1 and Occludin between the HaCaT cells; in addition, the cistanche deserticola polysaccharide has remarkable effects on preventing damage of UVB to HaCaT cells, improving the migration rate of the HaCaT cells, promoting wound healing and the like. Based on the characteristics of the cistanche polysaccharide, the cistanche polysaccharide shows huge application value in preparation of related products for protecting skin barriers.

Provided are a probiotic composition for preventing and treating intestinal inflammation and a use thereof. The probiotic composition for preventing and treating intestinal inflammation comprises a Lactobacillus acidophilus LA85 strain and a Bifidobacterium longum subsp. BL36 strain. Provided are a new probiotic formulation method and a new strategy for preventing and treating intestinal inflammation. It has been found that the LA85 strain and the BL36 strain can cooperate with each other, promote each other, have a synergistic effect in preventing and treating intestinal inflammation, can reduce the concentrations of the pro-inflammatory cytokines TNF-α, IL-6, and IL-1β in the serum of mice, and increase the concentration of the anti-inflammatory cytokine IL-10; can increase the concentration of urolithin A in the serum of mice and significantly reduce the concentration of reactive oxygen species in the serum; and can significantly increase the levels of the intestinal barrier indicators tight junction protein-1, tight junction protein, and Claudin-1 in the serum of mice.

The application belongs to the technical field of traditional Chinese medicine polysaccharides, and particularly relates to carboxymethylized bergamot polysaccharide as well as a preparation method and application thereof. The carboxymethylized bergamot polysaccharide prepared by the preparation method can significantly improve the mRNA expression of tight junction proteins ZO-1 and Occludin in Caco-2 cells in a lipopolysaccharide-induced Caco-2 cell inflammatory injury model, and can relieve Caco-2 cell injury and maintain the integrity of the cell barrier through a mutual transformation pathway of pentose and glucuronic acid.

The invention discloses application of ursolic acid or ursolic acid derivatives in preparation of chicken coccidiosis-resistant feed or chicken coccidiosis-resistant drugs, and relates to the technical field of biological medicines. The chicken coccidiosis protozoon is chicken eimeria tenella, the ursolic acid derivative is oleanolic acid, and the ursolic acid derivative and ursolic acid are isomers. The chicken coccidiosis-resistant feed or the chicken coccidiosis-resistant drug has at least one of the following functions: reducing the cecum lesion value and the number of oocysts, and inhibiting the depth increase of crypts induced by chicken coccidiosis; weight loss caused by chicken coccidiosis infection is relieved; the expression of inflammatory factors caused by chicken coccidiosis infection is reduced, and the inflammatory factors comprise IL-6, IL-8, TNF-alpha and IFN-gamma; the expression of tight junction protein after chicken coccidiosis infection is promoted, and the tight junction protein comprises ZO-1, Claudin-1 and Occludin. The traditional Chinese medicine composition has the advantages of low toxicity, low residue, good anti-chicken coccidiosis effect, simplicity in preparation, suitability for batch production and the like.

The invention discloses Lactobacillus johnsonii and application thereof in alleviating intestinal damage caused by plateau hypoxia. The composite bacterial agent of the composition of Lactobacillus johnsonii YH1136 and Bacillus subtilis BS01 provided by the invention can effectively prevent, treat and alleviate intestinal damage caused by plateau hypoxia exposure. The composite bacterial agent can increase the expression levels of tight junction proteins such as Claudin‑1, Occludin and ZO‑1, and restore the intestinal barrier function damage caused by plateau hypoxia exposure; restore the expression level of intestinal pro-inflammatory cytokines; reduce the level of harmful bacteria Escherichia coli, and increase the level of beneficial bacteria Lactobacillus; improve diarrhea; and maintain body weight. The composite bacterial agent provided by the invention can be used to prepare a medicine for alleviating intestinal damage caused by plateau hypoxia exposure and a composition thereof, can also be used as an auxiliary product of existing therapeutic drugs and treatment methods, and can also be used as a microecological preparation in medicines or health products, and has a very broad application prospect.

The invention discloses application of compound tung leaf burn oil in preparation of a medicine for treating colitis. The compound tung leaf burn oil disclosed by the invention can show the effect of improving ulcerative colitis (UC) only when the compound tung leaf burn oil is used as an active substance independently or together with other medicine components. The compound tung leaf burn oil not only can up-regulate the expression of tight junction proteins ZO-1, Occludin and Claudin-1 in the intestinal tract and maintain the integrity of the barrier, but also can down-regulate the expression of proinflammatory mediators such as TNF-alpha, TLR4 and IL-18 in serum and improve the expression level of an anti-inflammatory factor IL-4, so that the inflammation of the intestinal tract and the organism is relieved, and the barrier function of the intestinal tract is effectively repaired. In addition, the compound tung leaf burn oil can also effectively relieve intestinal flora disorder caused by DSS and maintain the intestinal steady state.

The present invention discloses the application of vimentin in the preparation of a drug for the treatment of Guangzhou angiostrongylus disease. The present invention constructs a mouse infection model of Guangzhou angiostrongylus disease, and finds that the level of vimentin and its phosphorylation level in the brain tissue of mice in the late stage of infection are significantly increased, and the permeability of the blood-brain barrier is significantly increased. After knocking out vimentin using the Vimentin-knockout mouse model, it was found through magnetic resonance imaging and Evans blue experiments that the degree of blood-brain barrier damage in infected mice was effectively alleviated, the expression of AQP4, a molecule related to blood-brain barrier damage, was significantly reduced, and the expression of tight junction protein occludin was significantly increased. The research results of the present invention show that vimentin is a key regulatory factor involved in the destruction of the blood-brain barrier of Guangzhou angiostrongylus disease, and downregulating vimentin can play a role in the treatment of Guangzhou angiostrongylus disease. Vimentin can be used as a therapeutic target for Guangzhou angiostrongylus disease for the preparation or screening of drugs for the treatment of Guangzhou angiostrongylus disease.

The invention discloses a composition for improving ackermann abundance and inhibiting tumor growth and application, and belongs to the technical field of biological medicine. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-20 parts of pinellia ternate or 5-15 parts of hawthorn, 10-20 parts of pericarpium citri reticulatae, 5-15 parts of poria cocos, 2-11 parts of honey-fried licorice root, 2-11 parts of ginger and 2-11 parts of dark plum. The composition provided by the invention affects the intestinal flora structure and improves the abundance of Ackerman bacteria in the intestinal tract; the number of goblet cells and the expression of intestinal tight junction proteins ZO-1 and Occludin are increased, and the barrier function of the intestinal tract is improved; the number of CD8 < + > T cells and GZMB < + > cells in a tumor microenvironment is increased, and the effect of inhibiting tumor growth is achieved.

The present invention discloses the application of Hamaudol in improving acute kidney injury and intestinal barrier function, and belongs to the field of drug development technology. The present invention finds that by intraperitoneally injecting the Chinese medicine monomer Hamaudol into mice, the intestinal barrier function can be significantly improved, the expression of tight junction proteins ZO-1 and Occludin in the intestinal tract of mice can be increased, and the serological indicators of acute kidney injury can be reduced at the same time, the pathological changes of renal tubular epithelial cells in mice with acute kidney injury can be improved, the expression of inflammatory factors in the kidney can be downregulated, and apoptosis and oxidative damage can be improved. Thus, acute kidney injury is prevented and treated, and a new target is provided for the treatment of acute kidney injury.

The application discloses an albumin postbiotic peptide and application thereof in preparation of a medicine for relieving or treating food allergy, and belongs to the technical field of bioactive peptides. The albumin postbiotic peptide is prepared from egg white protein powder through enzymolysis, inoculation of fermentation lactobacillus mucus IOB802, fermentation and inactivation again. The polysaccharide content in the albumin postbiotic peptide is as high as 1860.74 mg / 100g, the albumin postbiotic peptide can regulate immune balance, reduce allergy-related factors such as IgE and IL-4 and histamine level, increase IgG2a antibody level, reduce infiltration of eosinophils and mast cells in jejunum tissue, down-regulate expression of proinflammatory factors such as IL-25 and TSLP, up-regulate tight junction proteins such as ZO-1 and Occludin, repair intestinal barrier, block penetration of allergens and relieve food allergy symptoms.

A novel Lactobacillus rhamnosus KBL2290 strain exhibits various activities such as improving intestinal flora, anti-inflammatory, and strengthening intestinal tight junctions. The strain may increase intestinal flora of Akkermansia genus, Lactobacillus genus, Ruminococcus genus or Prevotella genus, suppress an expression of interleukin 1-beta (IL-1B), interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 12p40 (IL-12p40), interleukin 13 (IL-13), or interleukin 17A (IL-17A), suppresses an expression of chemokine ligand 2 (CCL2) or chemokine ligand 1 (CXCL1), suppress an expression of cyclooxygenase 2 (Cox-2) or nitric oxide synthase (iNOS), promote an expression of interleukin 10 (IL-10) or transforming growth factor-β (TGF-β), and increase an expression of Zo-1 or Occludin. A pharmaceutical composition including the strain may prevent or treat inflammatory bowel disease.

The application discloses a recombinant lactobacillus casei expressing sialyltransferase ST6GALNAC1, and belongs to the field of genetic engineering and microbial technology. The recombinant bacterium is obtained by cloning the ST6GALNAC1 gene into a pPG612 vector and electrotransforming the ST6GALNAC1 gene into lactobacillus casei ATCC393. Experiments show that the engineering bacterium can significantly enhance glycosylation modification of intestinal mucus protein MUC2, improve expression of tight junction proteins (ZO-1, Occludin and Claudin-1), inhibit activation of a p38 / MAPK inflammatory pathway, and regulate intestinal flora structure, thereby effectively relieving intestinal injury and systemic inflammatory response caused by salmonella. The application provides a strain basis and technical support for development of a new type of oral microecological preparation.

The invention relates to the technical field of natural medicine application, and discloses a maggot fatty acid active ingredient composition and application thereof, and a high-purity fatty acid composition with a specific ingredient spectrum is obtained through an optimized supercritical CO2 extraction and molecular distillation combined technology. The composition is proved to be capable of treating UC through a multi-target and multi-channel synergistic effect for the first time: proinflammatory factors are reduced by inhibiting classical inflammatory pathways such as NF-kappa B, oxidative stress is relieved by activating an Nrf2 / HO-1 antioxidant pathway, expression of intestinal tight junction proteins (such as ZO-1 and Occludin) is specifically up-regulated so as to repair an intestinal mechanical barrier, and the UC treatment effect is improved. Meanwhile, the metabolism of short-chain fatty acid of intestinal flora is regulated so as to improve the microecology of the intestinal tract. Animal experiments show that the curative effect of the composition is superior to that of a positive drug 5-ASA, the side effect is small, and a brand-new solution derived from natural drugs is provided for solving the UC treatment dilemma.

The invention belongs to the technical field of microorganisms, and discloses a preparation method of synbiotics-loaded pH-responsive emulsion beads and application of the synbiotics-loaded pH-responsive emulsion beads in targeted improvement of colitis. Taking a mixed solution of activated and cultured probiotic bacterial sludge and fructo-oligosaccharide as a W1 phase; mixing the W1 phase with the oil phase, shearing and homogenizing to obtain a W1 / O emulsion; dispersing into a W2-phase aqueous solution dissolved with polysaccharide-protein mixed nanoparticles, and shearing and homogenizing to obtain a W1 / O / W2 dual emulsion; and cross-linking the double emulsion with polylysine, adding a sodium alginate solution, and then dropwise adding into a calcium chloride solution for curing to obtain the emulsion condensate beads. The synbiotics are loaded in the emulsion gel beads, so that the emulsion gel beads have excellent biocompatibility, enzyme triggering property and pH responsiveness. Experiments show that the emulsion gel beads improve the UC model rat colon shortening, repair the intestinal mucosa barrier, reduce the content of inflammatory factors IL-1beta, IL-6 and TNF-alpha, increase the content of an anti-inflammatory factor IL-10, increase the expression of tight junction proteins ZO-1, Claudin-1 and Occludin and regulate the intestinal flora balance of rats through synergistic interaction.

The invention belongs to the technical field of biology and bioinformatics, and particularly relates to wheat oligopeptide with anti-inflammatory and anti-oxidation activity as well as engineering bacteria and a screening method of the wheat oligopeptide. The invention provides two peptide fragments RLSYQFPFYP and KCENEECTFP which are derived from wheat oligopeptides and have anti-inflammatory and antioxidant activity, and also provides a construction method of engineering bacteria capable of expressing the peptide fragments and a method for rapidly screening the peptide fragments from functional proteins. Experiments prove that the RLSYQFPFYP can relieve the reduction of the mRNA expression level of CaSR / RAC / PLC gamma1 caused by H2O2, improve the protein expression of Occludin and Claudin-1, and reduce the apoptosis of cells; the KCENEECTFP can relieve the reduction of the mRNA expression level of Nrf2 caused by H2O2, and reduce the expression of inflammatory factors TNF-alpha and IL-8; the provided engineering bacteria can be used as a safe and large-scale active peptide production platform; the provided method for rapidly screening the peptide fragment from the functional protein can be used as a universal functional peptide rapid screening normal form, and a replicable and extensible technical framework is provided for discovery of novel peptide molecules with different physiological functions.

The invention provides application of astaxanthin in preparation of medicines for preventing and treating intestinal dysfunction and intestinal flora imbalance related to severe acute pancreatitis or repairing intestinal mucosal barrier. In-vivo experiments prove that the astaxanthin can significantly improve SAP-induced intestinal barrier injury, reduce the activity of serum diamine oxidase (DAO), repair a jejunum villus structure and up-regulate the expression of tight junction proteins (ZO-1, Occludin and Claudin); the mechanism relates to inhibition of local inflammatory response and oxidative stress, and specific correction of intestinal flora disorder, including recovery of proportion balance of phylum firmicalis and bacteroides, and improvement of abundance of beneficial bacteria such as lactobacillus murine and ruminococcus; the invention provides a new strategy for clinical treatment of SAP complicated with intestinal failure.

To provide a hyaluronan synthase 3 (HAS3) mRNA expression promoter with excellent action effect, to provide a serine palmitoyltransferase (SPT) mRNA expression promoter, to provide an aquaporin 3 (AQP3) mRNA expression promoter, to provide a claudin-1 mRNA expression promoter, to provide a claudin-4 mRNA expression promoter, and to provide an occludin mRNA expression promoter.SOLUTION: The present invention provides a hyaluronan synthase 3 (HAS3) mRNA expression promoter, a serine palmitoyltransferase (SPT) mRNA expression promoter, an aquaporin 3 (AQP3) mRNA expression promoter, a claudin-1 mRNA expression promoter, a claudin-4 mRNA expression promoter and an occludin mRNA expression promoter, each of which contains as an active ingredient one or more selected from the group consisting of cytosine, trimethylglycine, glucuronic acid, citric acid, nicotinamide, cytidine, 3-hydroxybutyric acid, glyceric acid, and uridine.SELECTED DRAWING: None

The application belongs to the field of biological medicine, and particularly relates to application of an extract of Pteronura dumerelli in preparation of a medicine for treating ulcerative colitis, and aims to solve the technical problems of weak mucosa repair capacity, high recurrence rate after drug withdrawal, prominent long-term application safety problem, poor drug response or drug resistance of part of patients, and poor economic accessibility of existing ulcerative colitis treatment medicines. The preparation of the extract comprises the following steps: edible soft tissues of Pteronura dumerelli are washed with clean water to remove impurities, and then subjected to tissue crushing and homogenization treatment in a preset low-temperature environment; a compound enzyme system composed of neutral protease and papain is added to perform mild limited enzymolysis, and active small-molecule peptides and polysaccharide components are reserved; after low-temperature centrifugation to remove precipitates, two-stage ultrafiltration membranes are used for grading purification, high-activity small-molecule anti-inflammatory repair components are enriched, and finally low-temperature vacuum concentration and sterile filtration are performed to obtain a light yellow water-soluble active extract. The extract can inhibit activation of a nuclear factor kappa B inflammatory pathway, down-regulate levels of tumor necrosis factor alpha, interleukin 6 and interleukin 1 beta proinflammatory factors, reduce intestinal inflammatory cascade reaction, up-regulate expression of tight junction proteins Occludin and Claudin-1, repair damaged intestinal epithelial barrier, promote ulcer mucosa regeneration and healing, and realize a double synergistic treatment effect of anti-inflammation and mucosa repair.

The application discloses a strain of salivary lactobacillus and application of exopolysaccharide produced by the strain in relieving colitis, and belongs to the technical field of microorganisms and the technical field of medicines. The salivary lactobacillus (Ligilactobacillus salivarius) CCFM1334 provided by the application can efficiently produce exopolysaccharide, and the yield is 185.6 mg / L. After the exopolysaccharide of the salivary lactobacillus (Ligilactobacillus salivarius) CCFM1334 provided by the application is used on colitis mice, the colitis symptoms of the mice can be significantly relieved, which is specifically reflected in the following aspects: the disease activity score index is significantly reduced, the weight loss is relieved, the colonic histopathology is relieved, the levels of proinflammatory factors TNF-alpha, IL-1beta, IL-6, INF-gamma and IL-17 are reduced, the level of anti-inflammatory factor IL-10 is increased, and the mRNA expression amounts of tight junction proteins ZO-1 and occludin are increased. Therefore, the exopolysaccharide of the salivary lactobacillus (Ligilactobacillus salivarius) CCFM1334 has great application prospect in the preparation of products for preventing and / or treating colitis.

The invention relates to the technical field of functional food processing, in particular to a method for enhancing intestinal barrier function regulating activity of galactooligosaccharide based on collagen peptide Maillard coupling and application of the method. According to the method for enhancing the intestinal barrier regulating activity of the galactooligosaccharide based on Maillard coupling of the collagen peptide, provided by the invention, the biological effect of the galactooligosaccharide in the aspect of regulating the intestinal barrier function can be remarkably improved; meanwhile, the obtained Maillard conjugate has remarkable advantages in the aspects of promoting mucous secretion of goblet cells, up-regulating expression of tight junction proteins ZO-1 and Occludin and reducing intestinal permeability. The method provided by the invention is simple and convenient to operate, industrialization is easy to realize, the obtained product can be used as a functional component related to intestinal health to be applied to the fields of food, functional food and the like, and the application value of galactooligosaccharide can be effectively improved.

The invention discloses application of Pediococcus pentosaceus PPSJ001 or peptidoglycan of the Pediococcus pentosaceus PPSJ001 in preparation of a product for preventing or treating intestinal inflammatory diseases, and the Pediococcus pentosaceus PPSJ001 is Pediococcus pentosaceus. The invention further discloses a preparation method of the Pediococcus pentosaceus PPSJ001 and a preparation method of the Pediococcus pentosaceus PPSJ001. According to the application research of the pediococcus pentosaceus PPSJ001 and peptidoglycan thereof in DSS-induced acute and chronic colitis mouse models, prophylactic or therapeutic gavage can obviously reduce the inflammation degree, relieve weight loss, restore the colon length and improve pathological damage of colon tissue. The pediococcus pentosaceus PPSJ001 can be used for promoting the expression of tight junction proteins ZO-1 and Occludin and mucoprotein Muc2 and improving the barrier function of intestinal mucosa. The key functional component is cell wall peptidoglycan, and the peptidoglycan can remarkably relieve the colitis disease in vivo, promote polarization of macrophages to a CD206 + M2 type in vitro and improve expression of anti-inflammatory related genes Arg1. Based on the unique functions, the pediococcus pentosaceus PPSJ001 or peptidoglycan thereof can be coordinated or complemented with other micro-ecological regulation means, and has a wide application prospect in medicine preparation.

The invention provides an application of fructus psoraleae polysaccharide in preparation of a medicine or health food for regulating an intestinal barrier function. Specifically, the fructus psoraleae polysaccharide acts on an intestinal tract. In the intestinal tract action process, the fructus psoraleae polysaccharide effectively improves damaged intestinal tract barrier repair; the number of CD4 + and CD8 + T cells in intestinal tracts is increased, and the immune barrier of the intestinal tracts is improved; according to the present invention, the expression of tight junction proteins Claudin-1, Occludin and ZO-1 can be promoted, the intestinal mechanical barrier can be repaired and enhanced, and the polypeptide can be used for preventing, relieving or treating intestinal barrier damage, has excellent performance in the regulation of the intestinal barrier function, and has good application prospects.